+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Lateral Epicondylitis Treatment Market 2019-2023 - Product Image

Global Lateral Epicondylitis Treatment Market 2019-2023

  • ID: 4752654
  • Report
  • February 2019
  • Region: Global
  • 119 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bayer AG
  • GlaxoSmithKline plc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • MORE
Lateral epicondylitis is common in people who participate in physical activities such as racket sports, hockey, canoeing, weight-lifting, wrestling, rowing, and swimming. Moreover, it can also occur in people who apply more pressure on extensor carpi radialis brevis and longus muscles of the forearm, as a part of their work. These people observe severe and long-term pain around the elbow if the condition is left untreated. Hence, various government and non-government organizations are initiating certain programs to increase awareness among people and avoid delay in diagnosis. Hence, an increase in the number of organizations and institutes that raise awareness among people about lateral epicondylitis is expected to drive the growth of the global lateral epicondylitis treatment market during the forecast period. Analysts have predicted that the lateral epicondylitis treatment market will register a CAGR of over 3% by 2023.

Market Overview

Growing prevalence of risk factors for lateral epicondylitis

The growing prevalence of these medical conditions is the major risk factor for the development of lateral epicondylitis. The increase in the number of patients with these diseases may develop lateral epicondylitis. This, in turn, is expected to aid in the use of available treatments and anticipated treatments and drive the growth of the global lateral epicondylitis treatment market during the forecast period.

Lack of approved treatment

Lateral epicondylitis is a common problem with many available treatment options, but largely recommended treatment option is the combination of corticosteroids, physiotherapy, and bracing. However, there is no approved treatment for lateral epicondylitis. Therefore, the lack of approved treatments in the market for lateral epicondylitis is expected to hamper the growth of the global lateral epicondylitis treatment market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the lateral epicondylitis treatment market during the 2019-2023, view the full report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • GlaxoSmithKline plc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Non-surgical treatment - Market size and forecast 2018-2023
  • Surgical treatment - Market size and forecast 2018-2023
  • Market opportunity by type
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits:
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Non-surgical treatment - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Non-surgical treatment - Year-over-year growth 2019-2023 (%)
Exhibit 22: Surgical treatment - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Surgical treatment - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Decision framework
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Bayer AG - Vendor overview
Exhibit 50: Bayer AG - Business segments
Exhibit 51: Bayer AG - Organizational developments
Exhibit 52: Bayer AG - Geographic focus
Exhibit 53: Bayer AG - Segment focus
Exhibit 54: Bayer AG - Key offerings
Exhibit 55: Bayer AG - Key customers
Exhibit 56: GlaxoSmithKline plc. - Vendor overview
Exhibit 57: GlaxoSmithKline plc. - Business segments
Exhibit 58: GlaxoSmithKline plc. - Organizational developments
Exhibit 59: GlaxoSmithKline plc. - Geographic focus
Exhibit 60: GlaxoSmithKline plc. - Segment focus
Exhibit 61: GlaxoSmithKline plc. - Key offerings
Exhibit 62: GlaxoSmithKline plc. - Key customers
Exhibit 63: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 64: Johnson & Johnson Services, Inc. - Business segments
Exhibit 65: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 66: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 67: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 68: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 69: Johnson & Johnson Services, Inc. - Key customers
Exhibit 70: Merck Sharp & Dohme Corp. - Vendor overview
Exhibit 71: Merck Sharp & Dohme Corp. - Business segments
Exhibit 72: Merck Sharp & Dohme Corp. - Organizational developments
Exhibit 73: Merck Sharp & Dohme Corp. - Geographic focus
Exhibit 74: Merck Sharp & Dohme Corp. - Segment focus
Exhibit 75: Merck Sharp & Dohme Corp. - Key offerings
Exhibit 76: Merck Sharp & Dohme Corp. - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer AG
  • GlaxoSmithKline plc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
  • MORE
Global Lateral Epicondylitis Treatment Market 2019-2023

The publisher recognizes the following companies as the key players in the global lateral epicondylitis treatment market: Bayer AG, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Merck Sharp & Dohme Corp., Pfizer Inc.

Commenting on the report, an analyst from the publishing team said: “The latest trend gaining momentum in the market is the increasing funds for research on lateral epicondylitis.”

According to the report, one of the major drivers for this market is the growing incidence of sport injuries will support the growth of market.

Further, the report states that one of the major factors hindering the growth of this market is the limited ongoing research on new therapies for the treatment of lateral epicondylitis can pose a challenge to te growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer AG
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services Inc.
  • Merck Sharp & Dohme Corp.
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll